vVARDIS, a Swiss high-growth dental company, and OrbiMed, a leading healthcare investment firm, recently announced the closing of a $35 million financing. The capital will support the company’s growth initiatives and global commercial expansion. vVARDIS is a developer and manufacturer of unique dental products under the Curodont brand, including its innovative drill-free treatment for early tooth decay—the world’s most common disease, according to the World Health Organization—without the need for a dentist’s drill. Last year’s rapid expansion of sales, with an initial focus on the U.S., has already resulted in thousands of dental clinics using the product and over 300,000 teeth treated in 2024. vVARDIS’ technology is already incorporated into lectures at renowned universities in the U.S. and Europe as a new standard of care for the treatment of early tooth decay.
The partnership between OrbiMed and vVARDIS is based on a shared vision to build a U.S. and global leader in innovative dental products. With the market shifting from invasive to non-invasive care, combined with the accelerated adoption of AI detection for early tooth decay, vVARDIS products are well-positioned to align with market trends. These innovative products allow dental practices to treat early tooth decay in just 5 to 10 minutes, saving dental professionals and patients hours of chair time.
“We are confident that vVARDIS has the scientific knowledge and capabilities to become a global powerhouse in the dental market. With its proprietary formulas and Curodont products, the company is positioned for rapid growth and to provide a drill-free option for early tooth decay. The company’s growth ambitions and focus on providing innovative solutions in the global dental market align with our investment strategy,” said Matthew Rizzo, general partner at OrbiMed.
“We are thrilled about the partnership with OrbiMed. The funding and expertise they bring will enhance our ability to better serve dental professionals and patients while fulfilling our vision to create a world where the treatment of early decay is pain-free, regenerative, and accessible to everyone. As dentists, we are excited to finally offer a solution for the treatment of early decay. Dental professionals have been waiting for decades for a drill-free treatment option. Curodont has the potential to broaden the scope of options available to dental practices, empowering them to enhance patient care,” commented Drs. Haley and Goly Abivardi, founders and co-CEOs of vVARDIS.
William Blair & Company acted as the exclusive financial advisor to vVARDIS, and McGuireWoods and Rüd Winkler served as legal counsel.
About Curodont
Curodontf products are vVARDIS’ proprietary solutions for treating early tooth decay—the subclinical signs of the world’s most prevalent disease—using a non-invasive, drill-free medical approach in the dental office. It is widely recognized that poor oral health can impact overall health, and untreated tooth decay can even lead to life-threatening conditions.¹ Nearly 80% of all patients show signs of early decay,² yet the majority leave the dental office without treatment,² increasing their risk of more severe disease. With Curodont, the dental team can non-invasively treat early tooth decay on the same day, rather than relying on a “watch-and-wait” approach.
Curodont empowers dental professionals to intervene early, helping to preserve the natural tooth structure.
About vVARDIS AG
vVARDIS is a disruptive Swiss healthcare company based in Zug, Switzerland, offering groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Swiss dentists, innovators, and award-winning entrepreneurs Drs. Haley and Goly Abivardi, DMDs, vVARDIS is the result of more than 25 years of research, paired with the founders’ commitment to making a meaningful impact on people’s lives—especially the underserved.
vVARDIS’ mission is to expand access to novel approaches in dental care, improving oral health as the foundation for overall well-being. vVARDIS science is backed by 25 years of research and more than 200 scientific publications, including meta-analyses, peer-reviewed clinical studies, and a long-term, peer-reviewed real-world evidence study, with hundreds of thousands of patients successfully treated.
For more information, visit vVARDIS at www.vVARDIS.com and LinkedIn.
About OrbiMed
OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, offering tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.
For more information, visit OrbiMed at www.OrbiMed.com.
REFERENCES
- Liu J et al. Int J Epidemiol. 2022;51:1291-1303
- Jacobsen ID et al. Eur Arch Paediatr Dent 2019;20:73-78|
